Form 4: CytomX Therapeutics Director Matthew Young Granted Stock Options

CytomX Therapeutics, Inc. Director Matthew P. Young was granted 38,000 stock options with an exercise price of $2.82, vesting fully by the earlier of June 11, 2026, or the 2026 Annual Meeting.

Summary

• Matthew P. Young, a Director of CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options.
• The transaction date for this grant was June 11, 2025.
• The exercise price for these stock options is $2.82 per share.
• The options are set to expire on June 10, 2035.
• The underlying shares subject to the option will vest and become exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the Issuer's 2026 Annual Meeting of stockholders.
• Vesting is contingent upon continuous service as a director until the vesting date.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of options aligns director interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event, not indicative of significant new positive or negative developments.

Positives

• The grant of stock options aligns the financial interests of Director Matthew P. Young with those of the company's shareholders, incentivizing long-term value creation.
• This is a standard form of compensation for directors, reflecting ongoing commitment and service to the company.

Negatives

• The grant of stock options, if exercised, could lead to a minor dilutive effect on existing shareholders, although the amount is relatively small.
• The value of the options is contingent on the future stock price exceeding the exercise price, meaning there is no guaranteed value until vested and exercised profitably.

Future Outlook

The vesting schedule for the stock options, contingent on continuous service, indicates an expectation of Matthew P. Young's continued role as a director through at least the 2026 Annual Meeting.

Industry Context

The granting of stock options to directors is a common practice across publicly traded companies, particularly in the biotechnology sector like CytomX Therapeutics, Inc. This form of equity compensation is used to attract and retain talent, and to align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a widely accepted practice within the U.S. public company landscape, including the biotechnology industry.
• While specific grant sizes vary based on company size, performance, and individual roles, this grant size for a director at a company of CytomX's profile appears to be within typical industry ranges for incentivizing long-term commitment.

Related Party Transactions

• The grant of stock options to Matthew P. Young, a Director of CytomX Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to better long-term decision-making. However, it also represents potential future dilution if options are exercised.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grant is part of the compensation structure for the company's leadership, reinforcing retention and performance incentives.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the date of the 2026 Annual Meeting of CytomX Therapeutics' stockholders, assuming continuous service.

Key Dates

Keywords

CytomX Therapeutics, CTMX, stock options, Form 4, insider transaction, director compensation, Matthew Young, equity compensation